Coronavirus (COVID-19) information & research hub

We are committed to combating COVID-19, from efforts to prevent infection and developing our understanding of risk factors and SARS-CoV-2's effect on the immune system, to treating outcomes of disease, from mild symptoms to serious illness.

We have donated nine million face masks to support healthcare workers in 49 countries, bolstered national COVID-19 testing efforts and initiated clinical trials to investigate our new and existing medicines to see how they could treat the infection.

Recognising the urgent need for a vaccine to defeat the virus in the early stages of the pandemic, we joined forces with the University of Oxford to bring together its world-class expertise in vaccinology with our global development and manufacturing capabilities. We accelerated clinical development and rapidly mobilised partnerships to support a global supply chain that provides a broad, timely and equitable supply of a vaccine around the world, if approved, and at no profit during the pandemic.

Complementing our vaccines approach, we also quickly mobilised research efforts to advance the development of a novel coronavirus-neutralising long-acting antibody combination (LAAB) for the potential prevention and treatment of COVID-19.

With the COVID-19 pandemic continuing to claim thousands of lives every day, we are moving quickly with our clinical trials, while following strict regulatory standards and good clinical practice, guided by robust independent data safety and monitoring boards. Given the unprecedented global impact of COVID-19 and the need for public information, we are committed to being transparent about this process.